Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (155641)	3/13/2002 12:17:56 PM
From: reaper	Read Replies (2) \| Respond to of 436258

I've got another one out of the SEPR mold. ICOS (ICOS). Near-term event upcoming, which is the PDUFA date (which I believe is 29 April '02, so 6 weeks away) for Cialis. Cialis is a small-molecule drug for erectile dysfunction (so a familiar malady to members of this board <g>). Drug is partnered with LLY, 50/50 split. They have two other drugs in late-stage pipeline, Pafase (Phase III) for sepsis (notoriously difficult to make a successful drug; note also that LLY sepsis drug Xigris has had a high-profile slow launch) and Sitaxsentan (Phase II) for pulmonary arterial hypertension. My opinion is that most of the value ($2.9 billion market cap, +/-) of ICOS is tied up in Cialis. So, like with Sepracor, if they get approved they're in good shape and if they get turned down they're hosed. Erectile dysfunction is not life threatening and there seem to already be good drugs on the market (again, maybe you guys can tell me how good the existing drugs are <g>) so the bar to approval would seem to me likely to be set pretty high. And we have our decision date coming up fairly soon. I'll try to remember to remind folks as we get closer to the decision date. Cheers